Neurocrine and Takeda Ink $2 Billion-Plus Neuroscience Development DealAdrenocorticotropic Hormone (ACTH) Drugs, Business, Clinical Data, Congenital Adrenal Hyperplasia (CAH), Deals, Drug Compounds, Genetic Diseases, Licensing, Partnerships, Product PipelinesSan Diego-based Neurocrine Biosciences is partnering with Japan’s Takeda Pharmaceutical to develop and commercialize molecules in Takeda’s early-to-mid-stage psychiatry pipeline. Read more June 16, 2020/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/06/Neurocrine-and-Takeda-Ink-2-Billion-Plus-Neuroscience-Development-Deal-BioSpace-6-16-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-06-16 15:40:412020-06-20 19:00:30Neurocrine and Takeda Ink $2 Billion-Plus Neuroscience Development Deal